• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺神经内分泌肿瘤G3级与胰腺神经内分泌癌:基础生物学及治疗方面的差异

Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment.

作者信息

Zhang Ming-Yi, He Du, Zhang Shuang

机构信息

Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

出版信息

World J Gastrointest Oncol. 2020 Jul 15;12(7):705-718. doi: 10.4251/wjgo.v12.i7.705.

DOI:10.4251/wjgo.v12.i7.705
PMID:32864039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7428799/
Abstract

In 2017 the World Health Organization revised the criteria for classification of pancreatic neuroendocrine neoplasms (pNENs) after a consensus conference at the International Agency for Research on Cancer. The major change in the new classification was to subclassify the original G3 group into well-differentiated pancreatic neuroendocrine tumors G3 (pNETs G3) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs), which have been gradually proven to be completely different in biological behavior and clinical manifestations in recent years. In 2019 this major change subsequently extended to NENs involving the entire digestive tract. The updated version of the pNENs grading system marks a growing awareness of these heterogeneous tumors. This review discusses the clinicopathological, genetic and therapeutic features of poorly differentiated pNECs and compare them to those of well-differentiated pNETs G3. For pNETs G3 and pNECs (due to their lower incidence), there are still many problems to be investigated. Previous studies under the new grading classification also need to be reinterpreted. This review summarizes the relevant literature from the perspective of the differences between pNETs G3 and pNECs in order to deepen understanding of these diseases and discuss future research directions.

摘要

2017年,世界卫生组织在国际癌症研究机构召开共识会议后,修订了胰腺神经内分泌肿瘤(pNENs)的分类标准。新分类中的主要变化是将原来的G3组细分为高分化胰腺神经内分泌肿瘤G3(pNETs G3)和低分化胰腺神经内分泌癌(pNECs),近年来已逐渐证明它们在生物学行为和临床表现上完全不同。2019年,这一主要变化随后扩展到累及整个消化道的神经内分泌肿瘤。pNENs分级系统的更新版本标志着对这些异质性肿瘤的认识不断提高。本综述讨论了低分化pNECs的临床病理、遗传和治疗特征,并将它们与高分化pNETs G3的特征进行比较。对于pNETs G3和pNECs(由于其发病率较低),仍有许多问题有待研究。新分级分类下的既往研究也需要重新解读。本综述从pNETs G3和pNECs的差异角度总结相关文献,以加深对这些疾病的理解并讨论未来的研究方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/8d6f90533f77/WJGO-12-705-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/21ee62fb0e9c/WJGO-12-705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/b6fc05bf8f66/WJGO-12-705-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/8d6f90533f77/WJGO-12-705-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/21ee62fb0e9c/WJGO-12-705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/b6fc05bf8f66/WJGO-12-705-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3899/7428799/8d6f90533f77/WJGO-12-705-g003.jpg

相似文献

1
Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment.胰腺神经内分泌肿瘤G3级与胰腺神经内分泌癌:基础生物学及治疗方面的差异
World J Gastrointest Oncol. 2020 Jul 15;12(7):705-718. doi: 10.4251/wjgo.v12.i7.705.
2
Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology.基于形态学的不同WHO 3级胰腺神经内分泌肿瘤的临床相关性
Endocr Connect. 2018 Feb;7(2):355-363. doi: 10.1530/EC-17-0388.
3
World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.世界卫生组织胰腺神经内分泌肿瘤分级分类:来自中国大型医疗机构的综合分析。
BMC Cancer. 2020 Sep 22;20(1):906. doi: 10.1186/s12885-020-07356-5.
4
Prediction of Pathological Grades of Pancreatic Neuroendocrine Tumors Based on Dynamic Contrast-Enhanced Ultrasound Quantitative Analysis.基于动态对比增强超声定量分析预测胰腺神经内分泌肿瘤的病理分级
Diagnostics (Basel). 2023 Jan 9;13(2):238. doi: 10.3390/diagnostics13020238.
5
Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.增强 CT 定量分析在鉴别高分化胰腺神经内分泌肿瘤和低分化神经内分泌癌中的应用。
Eur Radiol. 2022 Dec;32(12):8317-8325. doi: 10.1007/s00330-022-08891-4. Epub 2022 Jun 27.
6
Pancreatic neuroendocrine tumors.胰腺神经内分泌肿瘤
Intractable Rare Dis Res. 2017 Feb;6(1):21-28. doi: 10.5582/irdr.2017.01007.
7
Chromothripsis is a novel biomarker for prognosis and differentiation diagnosis of pancreatic neuroendocrine neoplasms.染色体碎裂是胰腺神经内分泌肿瘤预后及鉴别诊断的一种新型生物标志物。
MedComm (2020). 2024 Jul 10;5(7):e623. doi: 10.1002/mco2.623. eCollection 2024 Jul.
8
Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.150例连续性胰腺神经内分泌肿瘤患者的临床结局及长期生存情况:基于世界卫生组织2010年分级分类的综合分析
Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):261-268. doi: 10.1016/j.clinre.2017.09.004. Epub 2018 Jan 5.
9
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).神经内分泌肿瘤异质性给 2010 年世界卫生组织分类带来不确定性:来自西班牙肿瘤登记处(R-GETNE)的真实世界数据。
Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12.
10
An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms.miRNA 特征可预测胰腺神经内分泌肿瘤的分级。
Cancer Genomics Proteomics. 2023 Mar-Apr;20(2):154-164. doi: 10.21873/cgp.20370.

引用本文的文献

1
Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.胰腺神经内分泌肿瘤:信号通路与表观遗传调控
Int J Mol Sci. 2024 Jan 22;25(2):1331. doi: 10.3390/ijms25021331.
2
A relook at gastroenteropancreatic neuroendocrine tumours as per 2019 WHO classification-A tertiary centre experience.重新审视 2019 年 WHO 分类标准下的胃肠胰神经内分泌肿瘤——一项三级中心的经验。
Ir J Med Sci. 2023 Oct;192(5):2065-2070. doi: 10.1007/s11845-022-03217-1. Epub 2022 Nov 21.
3
DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.

本文引用的文献

1
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.帕博利珠单抗单药治疗经治转移性高级别神经内分泌肿瘤患者:两项前瞻性、非随机研究的联合分析。
Br J Cancer. 2020 Apr;122(9):1309-1314. doi: 10.1038/s41416-020-0775-0. Epub 2020 Mar 10.
2
Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.生长抑素与趋化因子 CXCR4 受体在胰腺腺癌与胰腺神经内分泌肿瘤中的表达。
J Cancer Res Clin Oncol. 2019 Oct;145(10):2481-2493. doi: 10.1007/s00432-019-03011-0. Epub 2019 Aug 26.
3
DNA 甲基化揭示了胰腺神经内分泌癌和胰腺神经内分泌肿瘤的不同起源细胞。
Genome Med. 2022 Mar 1;14(1):24. doi: 10.1186/s13073-022-01018-w.
The 2019 WHO classification of tumours of the digestive system.
2019年世界卫生组织消化系统肿瘤分类。
Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13.
4
Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm.不同肝脏神经内分泌肿瘤的B超及超声造影特征分析
World J Gastrointest Oncol. 2019 May 15;11(5):436-448. doi: 10.4251/wjgo.v11.i5.436.
5
C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group.C反应蛋白可能是整个胃肠胰神经内分泌肿瘤组的一个预后因素。
World J Gastrointest Oncol. 2019 Feb 15;11(2):139-152. doi: 10.4251/wjgo.v11.i2.139.
6
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.胃肠胰神经内分泌瘤 G3 患者的肽受体放射性核素治疗:一项多中心队列研究。
Endocr Relat Cancer. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424.
7
High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.高级胃肠道神经内分泌癌的管理和结局:一项国家癌症数据库研究。
Oncologist. 2019 Jul;24(7):911-920. doi: 10.1634/theoncologist.2018-0382. Epub 2018 Nov 27.
8
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.神经内分泌肿瘤的通用分类框架:国际癌症研究机构(IARC)和世界卫生组织(WHO)专家共识建议。
Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23.
9
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.《3 级神经内分泌肿瘤的肽受体放射性核素治疗:69 例患者的安全性和生存分析》
J Nucl Med. 2019 Mar;60(3):377-385. doi: 10.2967/jnumed.118.215848. Epub 2018 Aug 16.
10
Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.胰腺神经内分泌肿瘤中的热点 DAXX、PTCH2 和 CYFIP2 突变。
Endocr Relat Cancer. 2019 Jan 1;26(1):1-12. doi: 10.1530/ERC-18-0120.